NNRTIs: General Research
 Doravirine Can Be Co-Administered With Oral Contraceptives (May/June 2016)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- NNRTI Resistance Found in 12% of People Stopping Treatment With Undetectable Viral Load: Implications for Stock-Outs (March 24, 2014)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Switching to Stribild From Non-Nuke or Protease Inhibitor Regimens Works Well (March 14, 2014)
In The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014), from TheBodyPRO
- Transmitted NNRTI Resistance Rate Climbing in U.S. but Flat in Big European Countries (July 24, 2013)
From National AIDS Treatment Advocacy Project
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com
On TheBodyPRO.com
- NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From TheBodyPRO
- NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From TheBodyPRO
- HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From TheBodyPRO
- HIV JournalView: Dosing Adjustment Likely Needed for Statins Taken With NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO
- HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from TheBodyPRO
- The Clinical Relevance of Non-Nucleoside Reverse Transcriptase Inhibitor Hypersusceptibility: A Prospective Cohort Analysis (July 11, 2002)
In The XIV International AIDS Conference, from TheBodyPRO
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
In The XIV International AIDS Conference, from TheBodyPRO
- New Insights Into Mechanisms of HIV-1 Resistance to Reverse Transcriptase Inhibitors (February 27, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO
- Distinguishable Lipid Profiles Between PI and NNRTI Therapy May Carry Different Risk of Cardiovascular Disease (CVD) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO
- Associations Between Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Use and HIV-Associated Lipodystrophy Syndrome (HALS) in the Dagna-LipART Cohort Study (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from TheBodyPRO
- Safety of Non-PI-containing Regimens in People With High Viral Loads (August 17, 2000)
In STEP Ezine, from Seattle Treatment Education Project
- Patient Adherence With Twice-Daily Dosing of Nelfinavir Equivalent to NNRTIs When Given in Combination With Dual NRTIs (July 13, 2000)
In The XIII International AIDS Conference, from TheBodyPRO
- Primary Infection with HIV-1 with Reduced Drug Susceptibility Does Not Appear to Result from Point Source Transmission (January 31, 2000)
In The 7th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO
- Reduced Susceptibility to NRTI Is Associated With NNRTI Hypersensitivity in Virus From HIV-1-Infected Patients (January 31, 2000)
From Seattle Treatment Education Project
- Trials & Errors: Studies Look at Which Combinations Are Better (February 1999)
Clinical trials using NNRTIs with or instead of protease inhibitors.
From Seattle Treatment Education Project
|
Advertisement
|
Email
Glossary
